Nanostructured lipid carriers (NLC), comprises of a blend of solid and liquid lipids which
results in a partially crystallized lipid system and imparts many advantages over solid lipid …

The treatment of the posterior-segment ocular diseases, such as age-related eye diseases
(AMD) or diabetic retinopathy (DR), present a challenge for ophthalmologists due to the …

Dry eye disease (DED) is a frequently observed eye complaint, which has recently attracted
considerable research interest. Conventional therapy for DED involves the use of artificial …

During the past decade, the number of studies describing nanostructured lipid carriers
(NLCs)-based formulations has been dramatically increased. The raise in NLC exploitation …

Due to complicated anatomical and physical properties, targeted drug delivery to ocular
tissues continues to be a key challenge for formulation scientists. Various attempts are …

Commercially available ocular drug delivery systems are effective but less efficacious to
manage diseases/disorders of the anterior segment of the eye. Recent advances in …

Ocular diseases may be treated via different routes of administration, such as topical,
intracameral, intravitreal, oral and parenteral. Among them the topical route is most accepted …

Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) were developed as
alternative to other colloidal carriers. They were designed to overcome lipid nanoemulsions …

Over the recent couple of decades, pharmaceutical field has embarked most phenomenal
noteworthy achievements in the field of medications as well as drug delivery. The rise of …

Ophthalmic inflammatory diseases, including conjunctivitis, keratitis, uveitis, scleritis, and
related conditions, pose considerable challenges to effective management and treatment …